A5028743667- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- CNS Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Sarcoma Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Monoclonal and Polyclonal Antibodies Research
- Acute Lymphoblastic Leukemia research
- Cutaneous lymphoproliferative disorders research
- Immune Cell Function and Interaction
- Genetic factors in colorectal cancer
- Ubiquitin and proteasome pathways
- Cancer Genomics and Diagnostics
- Chronic Myeloid Leukemia Treatments
- Cervical Cancer and HPV Research
- HER2/EGFR in Cancer Research
- Acute Myeloid Leukemia Research
- Multiple and Secondary Primary Cancers
- Cardiac tumors and thrombi
- Cancer Risks and Factors
- Glioma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Esophageal Cancer Research and Treatment
Skåne University Hospital
2016-2025
Lund University
2016-2025
Repatriation General Hospital
2022
Royal Adelaide Hospital
2022
Rigshospitalet
2015-2020
Zealand University Hospital
2020
Odense University Hospital
2015-2018
Aalborg University Hospital
2015-2018
Aarhus University Hospital
2009-2018
Karolinska University Hospital
2004-2018
Mantle cell lymphoma (MCL) is a heterogenic non-Hodgkin entity, with median survival of about 5 years. In 2008 we reported the early - based on observation time 4 years results Nordic Lymphoma Group MCL2 study frontline intensive induction immunochemotherapy and autologous stem transplantation (ASCT), more than 60% event-free at years, no subsequent relapses reported. Here present an update after 6·5 The overall are still excellent, response duration longer 10 7·4 However, six patients have...
In recent decades, the prognosis of Mantle Cell Lymphoma (MCL) has been significantly improved by intensified first-line regimens containing cytarabine, rituximab and consolidation with high-dose-therapy autologous stem cell transplantation. One such strategy is Nordic MCL2 regimen, developed Group. We here present 15-year updated results study after a median follow-up 11·4 years: For all patients on an intent-to-treat basis, overall progression-free survival was 12·7 8·5 years,...
Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab followed by maintenance therapy older patients untreated mantle-cell lymphoma.
BackgroundAdding ibrutinib to standard immunochemotherapy might improve outcomes and challenge autologous stem-cell transplantation (ASCT) in younger (aged 65 years or younger) mantle cell lymphoma patients. This trial aimed investigate whether the addition of results a superior clinical outcome compared with pre-trial ASCT an ibrutinib-containing treatment without ASCT. We also investigated is adding but ASCT.MethodsThe open-label, randomised, three-arm, parallel-group, superiority TRIANGLE...
Summary Mantle cell lymphoma ( MCL ) is an aggressive B lymphoma, where survival has been remarkably improved by use of protocols including high dose cytarabine, rituximab and autologous stem transplantation, such as the Nordic 2/3 protocols. In 2008, a international prognostic index MIPI was created to enable stratification clinical diverse patients into three risk groups. So far, in routine limited, it shown that inadequately separates low intermediate group patients. To improve outcome...
In recent years, the outcome of mantle cell lymphoma (MCL) has improved, especially in younger patients, receiving cytarabine-containing chemoimmunotherapy and autologous stem transplantation. Nevertheless, a proportion MCL patients still experience early failure. To identify biomarkers anticipating failure intensive chemotherapy MCL, we performed target resequencing DNA profiling purified tumor samples collected from enrolled prospective FIL-MCL0208 phase 3 trial (high-dose followed by...